Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine

Vaccine

Volumn 24, Issue 15, 2006, Pages 2781-2789

  Rendi Wagner, Pamela ^a   Shouval, Daniel ^b   Genton, Blaise ^c   Lurie, Yoav ^d   Rümke, Hans ^e   Boland, Greet ^f   Cerny, Andreas ^g   Heim, Markus ^h   Bach, Doris ⁱ   Schroeder, Manfred ^j   Kollaritsch, Herwig ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Centre de Vaccination et de Médecine des Voyages   (Switzerland)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g Ospedale Civico Lugano   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ Hesperion Ltd   (Switzerland)

^j Berna Biotech   (Switzerland)

more..

Author keywords

Hepatitis B; Mammalian cell derived PreS1 PreS2 S third generation vaccine; Seroprotection; Vaccination failure

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; HEPIMMUNE; PRES1 ANTIGEN; PRES2 ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; S ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATOMA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PRIORITY JOURNAL; PRURITUS; RASH;

ADULT; AGED; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; PROTEIN PRECURSORS;

EID: 33644892768     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.01.007     Document Type: Article

References (53)

1. World Health Organization. Fact sheet. www.who.int.
2. CDC. Fact sheet. www.cdc.gov.
3. Datamonitor. Strategic perspectives: hepatitis B and C - strategic developments in an immature market. DMHC1802, 24 September 2002.
4. EASL Jury. EASL International Consensus Conference on Hepatitis B. 13 September 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-40.
5. P. Rendi-Wagner, M. Kundi, H. Stemberger, G. Wiedermann, H. Holzmann, and H. Hofer Antibody-response to three recombinant hepatitis vaccines: comparative evaluation of multicenter travel-clinic based experience Vaccine 19 2001 2055 2060
6. K. Das, R.K. Gupta, V. Kumar, and P. Kar Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age forty years and response of a booster dose among nonresponders World J Gastroenterol 9 2003 1132 1134
7. D. Westmoreland, V. Player, D.C. Heap, and A. Hammond Immunization against hepatitis B - what can we expect? Epidemiol Infect 104 1990 499 509
8. J.L. Dienstag, B.G. Werner, B.F. Polk, D.R. Snydman, D.E. Craven, and R. Platt Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy Ann Intern Med 101 1984 34 40
9. D.E. Craven, Z.L. Awdeh, L.M. Kunches, E.J. Yunis, J.L. Dienstag, and B.G. Werner Nonresponsiveness to hepatitis B vaccine in health care workers: results of revaccination and genetic typing Ann Intern Med 105 1986 356 360
10. R.C. Wood, K.L. MacDonald, K.E. White, C.W. Hedberg, M. Hanson, and M.T. Osterholm Risk factors for lack of detectable antibody response following hepatitis B vaccination of Minnesota health care workers JAMA 270 1993 2935 2939
11. H.L. Bock, J. Kruppenbacher, R. Sanger, W. Hobel, R. Clemens, and W. Jilg Immunogenicity of a recombinant hepatitis B vaccine in adults Arch Intern Med 156 1996 2226 2231
12. A. Kramer, D. Sommer, E.G. Hahn, and E.O. Riecken German experimental hepatitis B vaccine - influence of variation of dosage schedule, sex and age differences on immunogenicity in health care workers Klin Wochenschr 64 1986 688 694
13. C.A. Alper, M.S. Kruskall, D. Marcus-Bagley, D.E. Craven, A.J. Katz, and S.J. Brink Genetic prediction of nonresponsiveness to hepatitis B vaccine N Engl J Med 321 1989 708 712
14. T. Hohler, C.U. Meyer, A. Notghi, B. Stradmann-Bellinghausen, P.M. Schneider, and R. Starke Influence of major histocompatibility complex class II and T cell V beta repertoire on response to immunization with HBsAg Hum Immunol 59 1998 212 218
15. D.R. Milich T and B cell recognition of hepatitis B viral antigens Immunol Today 9 1988 380 391
16. R.N. Gunson, D. Shouval, M. Roggendorf, H. Zaajer, H. Nicholas, and H. Holzmann Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients J Clin Virol 27 2003 213 230
17. G. Reiss, and E.B. Keeffe Review article: hepatitis vaccination in patients with chronic liver disease Aliment Pharmacol Ther 19 2004 715 727
18. STIKO Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2002 Epid Bull 28 2002 227 242
19. Department of Health Hepatitis D.M. Salisbury N.T. Begg Immunisation against infectious disease 1996 HMSO London
20. K.H. Heermann, U. Goldmann, W. Schwartz, T. Seyffarth, H. Baumgarten, and W.H. Gerlich Large surface proteins of Hepatitis B virus containing the Pre-S sequence J Virol 52 1984 396 402
21. D.R. Milich Immunological response to Pre-S antigens of the hepatitis B virus Viral Immunol 1 1987 83 96
22. A.R. Neurath, B.S. Jameson, and T. Huima Hepatitis NB virus proteins eliciting protective immunity Microbiol Sci 4 1987 45 51
23. A.R. Neurath, S.B. Kent, N. Strick, P. Taylor, and C.E. Stevens Hepatitis B virus contains pre-S gene-encoded domains Nature 315 1985 154 156
24. M.A. Petit, P. Maillard, F. Capel, and J. Pillot Immunochemical structure of the hepatitis B surface antigen vaccine. II. Analysis of antibody responses in human sera against envelope proteins Mol Immunol 23 1986 511 523
25. D.R. Milich, M.K. McNamara, A. McLachlan, G.B. Thornton, and F.V. Chisari Distinct H-2-linked regulation of T-cell responses to pre-S and S-regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S-region Proc Natl Acad Sci USA 82 1985 8168 8172
26. I. Yap, and S.H. Chan A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: a preliminary observation Ann Acad Med Singapore 25 1996 120 122
27. D. Shouval Hepatitis B vaccines J Hepatol 39 Suppl. 1 2003 S70 S76
28. D.R. Milich, G.B. Thornton, A.R. Neurath, S.B. Kent, M.L. Michel, and P. Tiollais Enhanced immunogenicity of pre-S region of hepatitis B surface antigen Science 228 1985 1195 1199
29. I. Yap, R. Guan, and S.H. Chan Recombinant DNA hepatitis B vaccine containing Pre-S component of the HBV coat protein - a preliminary study on immunogenicity Vaccine 10 1992 439 442
30. D. Shouval, Y. Ilan, R. Adler, R. Deepen, A. Panet, and Z. Even-Chen Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast derived vaccines Vaccine 12 1994 1453 1459
31. I. Yap, R. Guan, and S.H. Chan Study on the comparative immunogenicity of a recombinant DANN hepatitis B vaccine containing the pre-S components of the HBV coat protein with non-containing vaccines Gastroenterol Hepatol 10 1995 51 55
32. R. Raz, R. Dagan, A. Gallil, G. Brill, I. Jassis, and R. Koren Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children Vaccine 14 1996 207 211
33. B. Yerushalmi, R. Raz, O. Blondheim, E. Shumov, R. Koren, and R. Dagan Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates Pediatr Infect Dis 16 1997 587 592
34. M.Y. Shapira, E. Zeira, R. Adler, and D. Shouval Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine J Hepatol 34 2001 123 127
35. R. Raz, R. Koren, and D. Bass Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults Isr Med Assoc J 3 2001 328 332
36. K. Madalinski, S.P. Sylvan, U. Hellström, J. Mikolajewicz, E. Zembrzuska-Sadkowaska, and E. Piontek Antibody responses to PreS components after immunization of children with low doses of BioHepB Vaccine 20 2001 92 97
37. G. Leroux-Roels, I. Desombere, L. Cobbaut, M.A. Petit, P. Desmons, and P. Hauser Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines Vaccine 15 1997 1732 1736
38. P. Jacques, G. Moens, I. Desombere, J. Dewijngaert, G. Leroux-Roels, and M. Wettendorff The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population Vaccine 20 2002 3644 3649
39. M.-J. Kim, A.N. Nafziger, C.D. Harro, H.L. Keyserline, K.M. Ramsey, and G.L. Drusano Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response Vaccine 21 2003 1174 1179
40. E. Boxall, and M. Dennis HBVax II in non-responder to Engerix B Vaccine 16 1998 877 879
41. R. Clemens, R. Sänger, J. Kruppenbacher, W. Höbel, W. Stanburry, and H.L. Bock Booster immunization of low- and non-responder after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance Vaccine 15 1997 349 352
42. P.N. Goldwater Randomized, comparative trial of 20 μg vs. 40 μg Engerix B vaccine in hepatitis B vaccine non-responders Vaccine 15 1997 353 356
43. J.N. Zuckerman, A.J. Zuckerman, I. Symington, W. Du, A. Williams, and B. Dickson Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines Hepatology 34 2001 798 802
44. J.N. Zuckerman Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response - third generation pre-S/S-vaccines overcome non-response J Viral Hepatitis 5 Suppl. 2 1998 13 15
45. J.N. Zuckerman, C. Sabin, F.M. Craig, A. Williams, and A.J. Zuckerman Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study BMJ 314 1997 329 333
46. J.L. Fleiss Statistical methods for rates and proportions 2nd ed. 1981 John Wiley & Sons Inc. New York
47. W.W. Hauck, and S. Anderson A comparison of large sample confidence interval methods for differences of two binominal probabilities Am Stat 40 1986 318 322
48. T. Propst, A. Propst, K. Lhotta, W. Vogel, and P. Konig Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination Am J Kidney Dis 32 1998 1041 1045
49. H.S. Das, P. Sawant, R.G. Shirhatti, K. Vyas, S. Vispute, and S. Dhadpale Efficacy of low dose intradermal hepatitis B vaccine: results of a randomized trial among healthcare workers Trop Gastroenterol 23 2002 120 121
50. Xu Z-Y, et al. Intradermal and intramuscular vaccination for prevention of perinatal acquisition of HBV carriage. In: Proceedings of the 1987 International Symposium on Viral Hepatitis and Liver Disease. London, 26-28 May, 1987.
51. H.C. Whittle, W.H. Lamb, and R.W. Ryder Trials of intradermal hepatitis B vaccines in Gambian children Ann Trop Paediatr 7 1987 6 9
52. P.N. Goldwater, D.G. Woodfield, A.M. Ramirez, and I.S. Anzimlt Intradermal, low dose, short course hepatitis B vaccination N Z Med J 99 1986 703 705
53. Collaborative Group of Girona J.M. Mauri, and M. Valles Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients Nephrol Dial Transplant 12 1997 729 732